<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700622</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-117</org_study_id>
    <nct_id>NCT00700622</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks</brief_title>
  <official_title>A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate that TI® Inhalation Powder combined with
      Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2
    inhaler)
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change from Baseline in glycosylated hemoglobin at Week 16</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Diabetes, Type 1</condition>
  <arm_group>
    <arm_group_label>TI + Insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin lispro + Insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humalog (insulin lispro) in combination with Lantus (insulin glargine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Insulin</intervention_name>
    <description>Technosphere Insulin Inhalation Powder 15U or 30U</description>
    <arm_group_label>TI + Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Lantus-injectible supplied as 3mL (300 units) pens</description>
    <arm_group_label>Insulin lispro + Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <description>Humalog autopen cartridges pre-filled with 3mL (300 units)</description>
    <arm_group_label>Insulin lispro + Insulin glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥ 18 and ≤ 80 years old

          -  Clinical diagnosis of type 1 diabetes mellitus for more than 12 months

          -  Body mass index (BMI) ≤ 30 kg/m2

          -  Stable antidiabetic regimen of sc insulin therapy at a total daily dose ≤ 1.5
             IU/kg/day

          -  HbA1c &gt; 7.0% and ≤ 9.0%

          -  C-peptide level ≤ 0.30 pmol/mL

          -  Nonsmokers (includes cigarettes, cigars, pipes, and chewing tobacco) for at least the
             preceding 6 months

          -  Negative urine cotinine defined as ≤ 100 ng/mL

          -  Pulmonary function tests (PFTs):

               -  Forced expiratory volume in 1 second (FEV1) ≥ 70% Third National Health and
                  Nutrition Examination Survey (NHANES III) predicted

               -  FEV1 as a percentage of FEV1/forced vital capacity (FVC) ≥ 70% (NHANES III)
                  predicted

               -  Total lung capacity (TLC) ≥ 80% predicted (Intermountain Thoracic Society [ITS])

               -  Single breath carbon monoxide diffusing capacity of the lung,
                  hemoglobin-corrected (DLco-Hb) (uncorrected) ≥ 70% predicted

          -  For the subset of subjects having Doppler echocardiograms: right ventricular systolic
             pressure (RVSP) ≤ 40 mm Hg at Visit 1

          -  Written informed consent

        Exclusion Criteria:

          -  Treatment with any type of antidiabetic drugs, other than sc insulin, within the
             preceding 12 weeks

          -  Two or more severe hypoglycemic episodes within 6 months of screening or episode of
             severe hypoglycemia between Visit 1 and Visit 5

          -  Any hospitalization or emergency room visit due to poor diabetic control within 6
             months of Visit 1, or hospitalization or emergency room visit due to poor diabetic
             control between Visit 1 and Visit 5

          -  Severe complications of diabetes, in the opinion of the PI, including symptomatic
             autonomic neuropathy; disabling peripheral neuropathy; active proliferative
             retinopathy; nephropathy with renal failure, renal transplant, or dialysis; history of
             foot ulcers; nontraumatic amputations due to gangrene; or vascular claudication

          -  Previous exposure to an inhaled insulin product within 3 months of Visit 1

          -  History of insulin pump use within 6 weeks of Visit 1

          -  Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the
             trial, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a
             similar chemical structure

          -  Significant improvement in pre- to postbronchodilator spirometry at Visit 1 (defined
             as an increase of 12% and 200 mL in either FEV1 or FVC)

          -  History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or
             any other clinically important pulmonary disease (eg, obstructive sleep apnea)
             confirmed by pulmonary function testing or radiologic findings

          -  Inability to perform spirometry maneuvers meeting recommended American Thoracic
             Society (ATS) standards of acceptability and repeatability criteria

          -  Active respiratory infection (subject could return after 30 days from resolution for
             rescreening); if respiratory infection manifested after Visit 1 but before Visit 1
             PFTs, subject was to be scheduled for PFTs after 30 days from resolution of
             respiratory infection. An additional hemoglobin was to be required

          -  Major organ system diseases, including:

               -  Seizure disorder

               -  Significant cardiovascular dysfunction or history within 3 months of Visit 1, eg,
                  congestive heart failure (New York Heart Association [NYHA] Class III or IV), or
                  serious arrhythmia, myocardial infarction, cardiac surgery, recurrent syncope,
                  transient ischemic attacks, or cerebrovascular accident

               -  Uncontrolled hypertension with a systolic blood pressure &gt; 180 mm Hg or diastolic
                  blood pressure &gt; 110 mm Hg at Visit 1 despite pharmacologic treatment

               -  Nephrotic syndrome; renal dysfunction or disease; serum creatinine &gt; 2.0 mg/dL
                  (0.11 mmol/L) in men and &gt; 1.8 mg/dL (0.1 mmol/L) in women; or blood urea
                  nitrogen (BUN) &gt; 50 mg/dL (2.8 mmol/L)

               -  Cancer (other than excised cutaneous basal cell carcinoma) within the past 5
                  years or any history of lung neoplasms

               -  History of active viral or cirrhotic hepatic disease or abnormal liver enzymes as
                  evidenced by serum aspartate aminotransferase (AST) or alanine aminotransferase
                  (ALT) ≥ 3 times the upper limit of normal (ULN)

               -  Active infection (eg, human immunodeficiency virus [HIV], hepatitis) or history
                  of severe infection within 30 days of Visit 1

               -  Anemia (hemoglobin ≤ 10.5 g/dL for women or ≤ 11.5 g/dL for men)

               -  Diagnosis of systemic autoimmune or collagen vascular disease requiring previous
                  or current treatment with systemic corticosteroids, cytotoxic drugs, or
                  penicillamine

               -  Any concurrent illness, other than diabetes mellitus, not controlled by a stable
                  therapeutic regimen

          -  Current or previous chemotherapy or radiation therapy that might result in pulmonary
             toxicity

          -  Use of medications prescribed for weight loss (eg, sibutramine, orlistat) within 12
             weeks of Visit 1

          -  Any history of or current use of amiodarone

          -  Clinically significant abnormalities on screening laboratory evaluation (unless
             discussed with and approved by the medical monitor)

          -  Women who were pregnant, lactating, or planning to become pregnant during the trial

          -  Women of childbearing potential (defined as premenopausal and not surgically
             sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth
             control. Adequate birth control was defined as using oral, percutaneous, or
             transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide;
             or intrauterine devices. Postmenopausal for this trial included amenorrhea for 2 or
             more years or surgically sterile

          -  Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the
             opinion of the PI, would make the subject an unsuitable candidate for participation in
             the trial

          -  Exposure to any investigational medications or devices within 30 days before trial
             entry, or participation in another clinical trial while participating in this trial

          -  Unable or unlikely to comprehend and follow the trial protocol (including SBGM and
             diabetes education)

          -  Unable or unlikely to comprehend how to use the MedTone Inhaler or inability to use
             the device

          -  Unable or unlikely to follow a meal plan that included at least 2 meals/day (with or
             without a third meal or additional snacks)

          -  Noncompliance with medication or procedures that, in the PI's opinion, might affect
             the trial data or subject safety and that precluded the subject from further
             participation in the trial

          -  Any other concurrent medical or major psychiatric condition that, in the opinion of
             the PI, made the subject unsuitable for the clinical trial or could limit the validity
             of the informed consent or impair the subject's ability to participate in the trial

          -  For the subset of subjects having Doppler echocardiograms:

               -  Subjects with left ventricular ejection fraction (LVEF) ≤ 35% at Visit 1

               -  Subjects with known history of sickle cell disease

               -  Previous use of Redux® (dexfenfluramine) or Pondimin® (fenfluramine)

               -  History of valvular heart disease, including mild or greater aortic insufficiency
                  or moderate or greater mitral insufficiency

               -  Significant cardiovascular dysfunction or history within 12 months of Visit 1
                  (eg, congestive heart failure [NYHA Class III or IV]) or serious arrhythmia,
                  treatment with medications to control or treat arrhythmias, myocardial
                  infarction, cardiac surgery, recurrent syncope, transient ischemic attacks, or
                  cerebrovascular accident

               -  History of pulmonary embolism or deep venous thrombosis in the 12 months before
                  Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes/Lipid Management and Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Whittier Institute for Diabetes Clinical Trials</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorothy L &amp; James E Frank Diabetes Research Institute</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes Young Adult Clinic</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Billings Clinic Research Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Physicians East PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Your Diabetes Endocrine Nutrition Group, Inc.</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Diabetes Center Research Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Barrtlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Center -Fletcher Allen Health Care</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Diabetes Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>-90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPClin-Centro de Pesquisas Clinicas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>October 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2014</results_first_posted>
  <disposition_first_submitted>June 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2009</disposition_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The FPFV was May 30, 2008. Multinational trial conducted in the US and Brazil.</recruitment_details>
      <pre_assignment_details>2 week screening period prior to randomization – 276 Screened / 138 Eligible. 130 subjects were randomized; 138 screen failures and 8 discontinued prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TI + Insulin Glargine</title>
          <description>Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)</description>
        </group>
        <group group_id="P2">
          <title>Insulin Lispro + Insulin Glargine</title>
          <description>Humalog (insulin lispro) in combination with Lantus (insulin glargine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TI + Insulin Glargine</title>
          <description>Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)</description>
        </group>
        <group group_id="B2">
          <title>Insulin Lispro + Insulin Glargine</title>
          <description>Humalog (insulin lispro) in combination with Lantus (insulin glargine)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="11.82"/>
                    <measurement group_id="B2" value="39.4" spread="11.46"/>
                    <measurement group_id="B3" value="39.0" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.49" spread="13.270"/>
                    <measurement group_id="B2" value="74.18" spread="13.894"/>
                    <measurement group_id="B3" value="74.3" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.22" spread="9.238"/>
                    <measurement group_id="B2" value="169.61" spread="9.807"/>
                    <measurement group_id="B3" value="170.9" spread="9.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.07" spread="3.744"/>
                    <measurement group_id="B2" value="25.63" spread="3.141"/>
                    <measurement group_id="B3" value="25.3" spread="3.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.76" spread="0.550"/>
                    <measurement group_id="B2" value="7.62" spread="0.602"/>
                    <measurement group_id="B3" value="7.69" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.26" spread="10.445"/>
                    <measurement group_id="B2" value="87.31" spread="10.669"/>
                    <measurement group_id="B3" value="86.78" spread="10.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.06" spread="76.916"/>
                    <measurement group_id="B2" value="176.20" spread="67.268"/>
                    <measurement group_id="B3" value="177.15" spread="72.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c to Week 16</title>
        <description>Change from Baseline in glycosylated hemoglobin at Week 16</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Intent to Treat with Available Data at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro + Insulin Glargine</title>
            <description>Humalog (insulin lispro) in combination with Lantus (insulin glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c to Week 16</title>
          <description>Change from Baseline in glycosylated hemoglobin at Week 16</description>
          <population>Intent to Treat with Available Data at Week 16</population>
          <units>percentage of total hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.087"/>
                    <measurement group_id="O2" value="-0.03" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A sample size of 92 subjects in each group was required to complete the trial. Approximately 230 subjects were to be randomized to achieve 184 completers (assuming a 20% dropout rate). This would have provided 80% power for a noninferiority design to test the difference of a 4-month change in HbA1c levels between treatment groups, assuming the upper noninferiority margins Δ of 0.5% with a standard deviation of 1.2 and a 1-sided alpha of 0.025.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.119</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: From first dose to 30d post last dose AEs: From first dose to 30d post last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TI + Insulin Glargine</title>
          <description>Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)</description>
        </group>
        <group group_id="E2">
          <title>Insulin Lispro + Insulin Glargine</title>
          <description>Humalog (insulin lispro) in combination with Lantus (insulin glargine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Delayed recovery from anesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoglycemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the study results subject to MNKD rights herein.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>- Early termination of trial leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>MannKind Corporation</organization>
      <phone>201-983-5000</phone>
      <email>aboss@mannkindcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

